Background: Dolutegravir recently became the third integrase strand transfer inhibitor (INSTI) approved for use in HIV-1-infected individuals. In contrast to the extensive dataset for HIV-1, in vitro studies and clinical reports of dolutegravir for HIV-2 are limited. To evaluate the potential role of dolutegravir in HIV-2 treatment, we compared the susceptibilities of wild-type and INSTI-resistant HIV-1 and HIV-2 strains to the drug using single-cycle assays, spreading infections of immortalized T cells, and site-directed mutagenesis.
Findings: HIV-2 group A, HIV-2 group B, and HIV-1 isolates from INSTI-naïve individuals were comparably sensitive to dolutegravir in the single-cycle assay (mean EC 50 values = 1.9, 2.6, and 1.3 nM, respectively). Integrase substitutions E92Q, Y143C, E92Q + Y143C, and Q148R conferred relatively low levels of resistance to dolutegravir in HIV-2 ROD9 (2-to 6-fold), but Q148K, E92Q + N155H, T97A + N155H and G140S + Q148R resulted in moderate resistance (10-to 46-fold), and the combination of T97A + Y143C in HIV-2 ROD9 conferred high-level resistance (>5000-fold). In contrast, HIV-1 NL4-3 mutants E92Q + N155H, G140S + Q148R, and T97A + Y143C showed 2-fold, 4-fold, and no increase in EC 50 , respectively, relative to the parental strain. The resistance phenotypes for E92Q + N155H, and G140S + Q148R HIV-2 ROD9 were also confirmed in spreading infections of CEM-ss cells.
Conclusions:
Our data support the use of dolutegravir in INSTI-naïve HIV-2 patients but suggest that, relative to HIV-1, a broader array of replacements in HIV-2 integrase may enable cross-resistance between dolutegravir and other INSTI. Clinical studies are needed to evaluate the efficacy of dolutegravir in HIV-2-infected individuals, including patients previously treated with raltegravir or elvitegravir.
Findings
Human immunodeficiency virus type 2 (HIV-2) infection is a significant public health problem in West Africa and has been reported in other countries with socioeconomic ties to the region [1] . Dual HIV-1/HIV-2 infection also occurs in areas where the viruses co-circulate [2] [3] [4] [5] [6] . Historically, clinical outcomes of antiretroviral therapy in HIV-2 and HIV-1/HIV-2 dually positive patients have been poor, with high rates of immuno-virologic failure and emergent multidrug resistance [7] [8] [9] [10] [11] . Newer classes of antiretrovirals (ARV) with anti-HIV-2 activity could represent substantial improvements to the current therapeutic picture [12, 13] .
A growing body of evidence suggests that integrase strand transfer inhibitors (INSTI) might be particularly useful for HIV-2 treatment. Raltegravir and elvitegravir are both potent inhibitors of HIV-2 replication in culture [14] [15] [16] [17] [18] , and case reports and small case series (primarily involving ARV-experienced individuals) indicate that raltegravir and elvitegravir can reduce HIV-2 viral loads when combined with other suppressive ARV [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . As with HIV-1, changes at integrase residues Y143, Q148 or N155, together with other secondary replacements in the integrase protein (i.e., E92Q, T97A, G140S, and possibly others), confer resistance to raltegravir in HIV-2 [26, [28] [29] [30] [31] [32] [33] [34] [35] . The emergence of resistance to elvitegravir has not yet been reported in HIV-2-infected individuals but will likely involve these same three pathways based on studies of HIV-1 [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] and the extensive crossresistance seen between raltegravir and elvitegravir in HIV-2 in culture [15, 17] . Clinical trials of raltegravir-and elvitegravir-containing regimens for first-line HIV-2 treatment are now underway and are expected to yield data within the next few years (NCT01605890, NCT02150993, NCT02180438).
A third strand transfer inhibitor, dolutegravir, was recently approved by the United States Food and Drug Administration (FDA) for use in both INSTI-naïve and INSTI-experienced HIV-1 patients. Although dolutegravir has been extensively evaluated for HIV-1 treatment, few studies have examined its potential use in HIV-2-infected individuals. Charpentier and colleagues reported that HIV-2 ROD, HIV-1 BRU , and eight HIV-2 isolates from INSTI-naïve patients were comparably susceptible to dolutegravir in spreading infections of peripheral blood mononuclear cells (PBMC) (EC 50 = 0.2-4 nM) and that three HIV-2 isolates from raltegravir-treated individuals with consensus integrase genotypes G140S + Q148R (group A), G140T + Q148R + N155H (group A), and T97A + Y143C (group H) were 63-, 9-, and 5-fold resistant to dolutegravir, respectively, in PBMC [51] . In addition, the manufacturer of dolutegravir (ViiV Healthcare) reported that EC 50 values against three clinical isolates of HIV-2 ranged from 0.09 nM to 0.61 nM in PBMC assays, and that combinations of substitutions A153G + N155H + S163G and E92Q + T97A + N155H + S163D in HIV-2 integrase conferred 4-fold decreases in dolutegravir susceptibility, while E92Q + N155H and G140S + Q148R resulted in 8.5-fold and 17-fold decreases, respectively [52] .
The ability of dolutegravir to inhibit strains resistant to other INSTI is of particular importance-in HIV-1, mutations Q148H/K/R, together with secondary changes in the integrase protein, confer resistance to dolutegravir in cell culture [38, 47, [53] [54] [55] , and other mutations associated with diminished in vitro susceptibility to dolutegravir have been reported [56] [57] [58] [59] [60] [61] . In contrast, dolutegravir is fully active against HIV-1 variants bearing Y143 or N155 mutations (with or without secondary changes) in both single-cycle and spreading infection assays [38, 47, [53] [54] [55] , although it should be noted that Y143 and N155 mutants have been observed in raltegravir-experienced patients who subsequently failed dolutegravir-based regimens [62, 63] . In the VIKING-3 trial, dolutegravir response rates (<50 HIV-1 RNA copies/ml at week 24) declined from 79% (n = 100/126) for patients without Q148 mutations at baseline (including those with N155H, Y143C/H/R, T66A, E92Q, or historical evidence of INSTI resistance), to 58% (21/36) for patients with Q148 plus one additional secondary mutation, to 24% (5/21) for those with Q148 plus two or more secondary mutations [64] . Importantly, drug resistance testing is not widely available in West Africa, and thus, dolutegravir usage in many HIV-2-infected patients, including INSTI-experienced individuals, will depend on an algorithmic approach to treatment. To date, there are only two reports of dolutegravir treatment for HIV-2 infection ( [65, 66] ; n = 2 and 13 patients, respectively), with limited duration of follow-up.
In the present study, we examined the activity of dolutegravir against wild-type and INSTI-resistant HIV-2 strains using an indicator cell assay that restricts viral replication to a single cycle [15] . This methodology enables a direct comparison of HIV-1 and HIV-2 drug susceptibility while avoiding potential confounders such as differences in replication rates, infectivity, cytopathic potential and cell-to-cell spread.
We initially compared the dolutegravir sensitivities of viruses derived from two prototypic full-length molecular clones: pNL4-3 (HIV-1 group M, subtype B) and pROD9 (HIV-2 group A). In head-to-head single-cycle assays, these two strains showed nearly identical doseresponse profiles ( Figure 1A ). Over multiple assays runs, the mean EC 50 values for dolutegravir (± standard deviation) were 1.5 ± 0.6 nM for HIV-1 NL4-3 and 2.3 ± 0.7 nM for HIV-2 ROD9 (n = 14 and 24 determinations, respectively). Dolutegravir was 3.6-fold more potent than raltegravir and 9.1-fold more potent than elvitegravir against HIV-2 ROD9 ( Figure 1B ). Other isolates from ARV-naïve individuals displayed levels of dolutegravir sensitivity comparable to HIV-1 NL4-3 and HIV-2 ROD9 ( Figure 1C ). The aggregate EC 50 values for HIV-1, HIV-2 group A, and HIV-2 group B were 1.3 ± 0.2 nM, 1.9 ± 0.5 nM, and 2.6 ± 0.9 nM, respectively. When subjected to a one-way ANOVA, only the comparison between HIV-1 and HIV-2 group B reached statistical significance (p < 0.05); this modest difference was attributable to the slightly higher EC 50 for HIV-2 EHO (3.6 ± 1.9 nM) ( Figure 1C) . Notably, HIV-2 EHO integrase contains a glutamate at position 146, whereas other HIV-2 isolates (as well as HIV-1) encode glutamine at this site [67, 68] . Substitutions at Q146 have been observed in HIV-1 following in vitro selections with elvitegravir and other, investigational INSTI [18, 69, 70] . To our knowledge, Q146 mutations have not been observed in HIV-2 variants selected in culture, nor have they been reported in HIV-2 patients treated with INSTI-based regimens.
To examine potential resistance pathways in HIV-2, we tested the activity of dolutegravir against a panel of site-directed mutants of HIV-2 ROD9 using the singlecycle assay. These variants contained amino acid replacements in the integrase protein that are associated with raltegravir and elvitegravir treatment; their phenotypes with respect to raltegravir and elvitegravir susceptibility have been reported elsewhere [14, 15] . Single amino acid changes T97A, G140S, Q148H and N155H had no significant effect on dolutegravir sensitivity (p > 0.05, ANOVA; Figure 2A ). In contrast, mutants E92Q, Y143C, E92Q + Y143C, Q148K, and Q148R were resistant to dolutegravir, with EC 50 values 2.3-9.3-fold greater than that of the parental strain (Figure 2A) , and variants E92Q + N155H, T97A + N155H and G140S + Q148R exhibited 11-33-fold resistance to the drug (p < 0.05, ANOVA; Figure 2A and B). In experiments with T97A + Y143C HIV-2 ROD9 , dolutegravir concentrations as high as 10 μM failed to reduce viral replication by 50% (Figure 2A and C; EC 50 > 10 μM), although modest dose-dependent inhibition was apparent at doses ≥100 nM ( Figure 2C ).
Altogether, nine of the 13 HIV-2 integrase mutants tested were resistant to dolutegravir in the single-cycle assay (Figure 2A) .
We also evaluated the dolutegravir sensitivities of E92Q + N155H, T97A + Y143C, and G140S + Q148R HIV-2 ROD9 in three-day spreading infections of immortalized T cells (CEM-ss). These assays were preformed as previously described for the MT-2 T cell line [14] . The resultant EC 50 values for the parental strain, E92Q + N115H, and G140S + Q148R were 0.24, 2.1 and 73 nM, respectively, indicating 8.8-fold resistance to dolutegravir for E92Q + N115H and 300-fold resistance for G140S + Q148R. Despite repeated attempts using high multiplicities of infection (≥0.1) and prolonged incubation times (up to seven days), CEM-ss cultures inoculated with T97A + Y143C HIV-2 ROD9 failed to produce detectable levels of infectious virus, indicating a severe fitness defect. This result is consistent with the poor replication capacity previously reported for T97A + Y143C HIV-2 ROD9 [15] . Lastly, we performed a head-to-head comparison of the phenotypes conferred by E92Q + N155H, G140S + Q148R, and T97A + Y143C in HIV-1 NL4-3 and HIV-2 ROD9 in the single-cycle assay. G140S + Q148R resulted in slight resistance to dolutegravir in HIV-1 NL4-3 (3.5-fold; p <0.01, ANOVA), whereas E92Q + N155H and T97A + Y143C had no statistically significant effect in the HIV-1 NL4-3 background ( Figure 2D ). These data are entirely consistent with previous studies of HIV-1 [38, 47, 53, 54] . In contrast, HIV-2 ROD9 mutants E92Q + N155H, G140S + Q148R, and T97A + Y143C were all resistant to dolutegravir (p < 0.0001, ANOVA) and showed EC 50 values 4-, 21-and >5000-fold greater than those seen for equivalent mutants of HIV-1 NL4-3 , respectively ( Figure 2D ). EC 50 and fold change values for all HIV-1 NL4-3 and HIV-2 ROD9 integrase mutants tested in this study, together with the corresponding EC 50 values for the parental wild-type clones, are compiled in Table 1 .
Taken together, our results indicate that prototypic HIV-1 and HIV-2 strains, as well as HIV-1 and HIV-2 isolates from INSTI-naïve individuals, are comparably sensitive to dolutegravir in a single cycle of viral replication in MAGIC-5A indicator cells (Figure 1 ). These findings complement previous data from spreading infections of PBMC [51] -using a different methodology and target cell type-and suggest that dolutegravir would be an appropriate treatment choice for INSTI-naïve HIV-2 patients when combined with other HIV-2-active ARV. We also report the effects of raltegravir-associated mutations on dolutegravir susceptibility using site-directed mutagenesis of genetically-defined HIV-1 and HIV-2 molecular clones (pNL4-3 and pROD9, respectively).
Our analysis shows that equivalent amino acid changes in the integrase proteins of HIV-1 and HIV-2 can have differing effects on dolutegravir susceptibility ( Figure 2D ) and that, in HIV-2 ROD9 , integrase changes Q148K, T97A + Y143C, E92Q + N155H, T97A + N155H, and G140S + Q148R confer moderate to high levels of dolutegravir resistance (≥10-fold; Figure 2A -C and Table 1 ). We cannot exclude the possibility that the resistance levels observed in our site-directed HIV-2 mutants are specific to the ROD9 molecular clone, as the genetic context within integrase can have a substantial impact on the phenotypic expression of INSTI resistance [71, 72] . For example, in the aforementioned study by Charpentier et al. Curve fits were generated as described in Figure 1A. (D) Comparative analysis of equivalent site-directed mutants of HIV-1 and HIV-2 integrase. Each point is the result of a single dose-response assay performed as described in Figure 1A . Horizontal bars indicate the mean EC 50 values for each strain. Red arrows and text indicate fold increases in the mean EC 50 values for HIV-2 relative to HIV-1. ANOVA results for these data are described in the main text. In all panels, error bars represent standard deviations. 
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